News
The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...
Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...
19h
Zacks Investment Research on MSNLilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...
Silver Oak Securities recently purchased 4,344 shares of CVS Health valued at $292,000, signaling fresh investor confidence.
Wall Street analysts are overwhelmingly bullish on Boston Scientific, with 90% rating it a Strong Buy and another 6.7% rating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results